Navigation Links
Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
Date:11/24/2008

tion will not be completed; general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007 and Omrix's Form 10-K as filed with the SEC on March 17, 2008. Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com, www.Omrix.com or on request from Johnson & Johnson or Omrix. Neither Johnson & Johnson nor Omrix undertakes to update any forward-looking statements as a result of new information or future events or developments.)

Additional Information

The tender offer described in this release has not yet commenced, and this release is neither an offer to purchase nor a solicitation of an offer to sell securities. At the time the tender offer is commenced, Johnson & Johnson will file a tender offer statement with the U.S. Securities and Exchange Commission (SEC). Investors and Omrix stockholders are strongly advised to read the tender offer statement (including an offer to purchase, letter of transmittal and related tender offer documents) and the related solicitation/recommendation statement that will be filed by Omrix with the SEC, because they will contain important information. These documents will be available at no charge on the SEC's website at
'/>"/>

SOURCE Johnson & Johnson
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
2. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
3. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
4. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
5. Johnson & Johnson Announces Changes to Accelerate Growth
6. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
7. Two-time Defending NASCAR Sprint Cup Series Champion Jimmie Johnson Joins the Team at CORD:USE Cord Blood Bank to Help Win the Race for Life
8. MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care
9. Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets
10. Craig Johnson Joins Ardea Biosciences Board of Directors
11. Migenix averts proxy contest; reaches agreement with DJohnson holdings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... life sciences industry faces a host of policy ... and nationally, SAN FRANCISCO, Jan. 10 ... providing a broad overview of,the productivity of Northern ... science research cluster in the world. To ensure,continued ...
... France, January 10 Transgene,(Euronext Paris: FR0005175080) announces ... its therapeutic vaccine TG4010,(MVA-MUC1-IL2) as an adjunct to ... lung cancer (NSCLC)., This on-going trial is ... assess the efficacy of TG4010 in combination with ...
... BIRMINGHAM, Alabama,Jan. 10 CANTOX HEALTH SCIENCES INC. ... regulatory consulting firm with,specialized expertise in the areas ... Agriculture, Biotech & Consumer Products announces,the launch of ... their,Pharmaceutical & Healthcare Division., For the past ...
Cached Biology Technology:Bioscience Group Warns Policymakers Against Complacency 2Bioscience Group Warns Policymakers Against Complacency 3Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 2Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 3Cantox Announces the Launch of Ashuren Health Sciences Pharmaceutical Division 2
(Date:4/17/2014)... researchers have detected new early-warning signs of the potential ... have far-reaching implications for the diagnosis and treatment of ... million Americans. , "We had not expected to see ... stages," said Ann Elsner, professor and associate dean in ... the study. "We set out to study the early ...
(Date:4/17/2014)... full of wild animals and plant life, but there,s ... churning away in the soil, decomposing organic matter and ... role these fungi play in ecological systems, their identities ... scientists has generated a genetic map of more than ... was published this week in the Proceedings of ...
(Date:4/17/2014)... Modern View of Domestication," a special feature of ... Sciences ( PNAS ) published April 29, raises ... our deep history that most of us take for ... people in many spots around the globe shifted from ... livestock and plants. , It seems so straightforward and ...
Breaking Biology News(10 mins):New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
... research at the Hebrew University of Jerusalem sheds light ... themselves indefinitely and to differentiate into all types of ... challenge in modern biology, could expedite the use of ... If scientists can replicate the mechanisms that make pluripotency ...
... Calif. As spatial planning is used increasingly to manage ... the best ways to use and refine the various spatial ... of the most common methods, which limit or entirely curtail ... in the early edition of the Proceedings of the ...
... used tiny, artificial fiber scaffolds thousands of times smaller than ... into cartilage, the shock-absorbing lining of elbows and knees that ... 4 in the Proceedings of the National Academy of ... both laboratory and animal models. While the findings are still ...
Cached Biology News:Researchers identify mechanisms that allow embryonic stem cells to become any cell in the human body 2Refining the tool kit for sustainable fisheries 2Refining the tool kit for sustainable fisheries 3Nanoscale scaffolds and stem cells show promise in cartilage repair 2Nanoscale scaffolds and stem cells show promise in cartilage repair 3
... PowerPac basic power supply are used for submerged ... gels. The Mini-Sub cell GT cell includes a ... 7 x 7 cm UV-transparent gel tray with ... mm fixed-height combs (8- and 15-well). The PowerPac ...
... PowerPac basic power supply are used for submerged ... gels. This Model 96 cell includes a buffer ... tray with fluorescent ruler, and a gel caster. ... V, provides output of 10-300 V, 4-400 mA, ...
... The Sub-Cell Model 192 and PowerPac basic power ... of nucleic acids in agarose gels. This Model ... x 15 cm UV-transparent gel tray with fluorescent ... power supply, 100-120 and 220-240 V, provides output ...
... The Sequi-Gen GT and PowerPac 3000 system, ... using a 38 x 30 cm vertical slab ... GT electrophoresis cell, which is capable of separating ... an integral plate chamber (IPC) assembly (IPC and ...
Biology Products: